These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30694839)

  • 1. Novel Approaches for Systemic Mastocytosis.
    Fletcher L; Borate U
    Curr Opin Hematol; 2019 Mar; 26(2):112-118. PubMed ID: 30694839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis.
    Baird JH; Gotlib J
    Curr Hematol Malig Rep; 2018 Oct; 13(5):407-416. PubMed ID: 30155614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.
    Schlenk RF; Kayser S
    Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kit Mutations: New Insights and Diagnostic Value.
    Falchi L; Verstovsek S
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The new tool "
    Shomali W; Gotlib J
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):127-136. PubMed ID: 30504301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.
    Schneeweiss M; Peter B; Bibi S; Eisenwort G; Smiljkovic D; Blatt K; Jawhar M; Berger D; Stefanzl G; Herndlhofer S; Greiner G; Hoermann G; Hadzijusufovic E; Gleixner KV; Bettelheim P; Geissler K; Sperr WR; Reiter A; Arock M; Valent P
    Haematologica; 2018 May; 103(5):799-809. PubMed ID: 29439183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis.
    Gotlib J
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):643-661. PubMed ID: 28673393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
    Kayser S; Levis MJ; Schlenk RF
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avapritinib in the Treatment of Systemic Mastocytosis: an Update.
    Below S; Michaelis LC
    Curr Hematol Malig Rep; 2021 Oct; 16(5):464-472. PubMed ID: 34580817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avapritinib for advanced systemic mastocytosis.
    Gotlib J; Reiter A; DeAngelo DJ
    Blood; 2022 Oct; 140(15):1667-1673. PubMed ID: 35877999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis.
    Lübke J; Naumann N; Kluger S; Schwaab J; Metzgeroth G; Evans E; Gardino AK; Lengauer C; Hofmann WK; Fabarius A; Cross NCP; Reiter A; Jawhar M
    Leukemia; 2019 May; 33(5):1195-1205. PubMed ID: 30911112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.
    Kasamon YL; Ko CW; Subramaniam S; Ma L; Yang Y; Nie L; Shord S; Przepiorka D; Farrell AT; McKee AE; Pazdur R
    Oncologist; 2018 Dec; 23(12):1511-1519. PubMed ID: 30115735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches to treating advanced systemic mastocytosis.
    Gilreath JA; Tchertanov L; Deininger MW
    Clin Pharmacol; 2019; 11():77-92. PubMed ID: 31372066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis.
    Sly N; Gaspar K
    Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Mastocytosis: State of the Art.
    Farmer I; Radia DH
    Curr Hematol Malig Rep; 2024 Oct; 19(5):197-207. PubMed ID: 39187708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis.
    Pilkington H; Smith S; Roskell N; Iannazzo S
    Future Oncol; 2022 Apr; 18(13):1583-1594. PubMed ID: 35114819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approaches in the treatment of systemic mastocytosis.
    Quintas-Cardama A; Aribi A; Cortes J; Giles FJ; Kantarjian H; Verstovsek S
    Cancer; 2006 Oct; 107(7):1429-39. PubMed ID: 16948123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.
    Hartmann K; Gotlib J; Akin C; Hermine O; Awan FT; Hexner E; Mauro MJ; Menssen HD; Redhu S; Knoll S; Sotlar K; George TI; Horny HP; Valent P; Reiter A; Kluin-Nelemans HC
    J Allergy Clin Immunol; 2020 Aug; 146(2):356-366.e4. PubMed ID: 32437738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
    Gotlib J
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):34-46. PubMed ID: 36485158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
    Stone RM; Manley PW; Larson RA; Capdeville R
    Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.